May 2026 Research Update

This month added a clearer picture of what trofinetide (Daybue) can look like outside of clinical trials: many families noticed some positive changes, but stomach and bowel side effects were frequent and sometimes limited how long people stayed on the medicine. [1]

In a retrospective chart review of 55 people with Rett syndrome or MECP2-related disorders, caregivers commonly described improvements such as engagement, gait, and hand use, alongside measured decreases in Rett Syndrome Behavior Questionnaire scores at 3 months and 6 months. Because there was no comparison group and reports were collected in routine care, the results describe what was observed in this clinic rather than proving the medicine caused the changes. [1]

Side effects centered on the gastrointestinal tract: diarrhea was reported in nearly half of participants and vomiting in a smaller group, and some people stopped treatment within the first 12 weeks. The report also noted that families and clinicians often tried dose titration and supportive strategies to manage these effects, and no unexpected serious adverse events were reported. [1]

For families already hearing about trofinetide, this study mainly helps set expectations about the range of experiences seen in everyday practice, including both possible day-to-day changes and common side effects. It may matter now as a snapshot of real-world use, but it still leaves uncertainty about how much improvement is due to the medication versus other factors because there was no placebo or blinding. [1]

These studies highlight how much caregiver-reported measures shape our understanding of daily functioning in Rett syndrome, and they point to two practical messages: behavior patterns may look fairly steady across ages in some groups, and families value communication services most when support feels well-resourced and responsive. [2] [3]

In a Korean cross-sectional study of 66 females with Rett syndrome, the strongest reported difficulties were in hand behaviors, and scores across behavioral domains did not show a clear link with age. Among those who completed an autism rating scale, a substantial portion scored in the severe range, which the authors interpreted as supporting a stable behavioral profile across ages in this sample. [2]

In a Spanish survey of 36 families of children with Rett syndrome or Angelman syndrome receiving early childhood speech-language therapy, families linked perceived quality to practical supports like resources and facilities and to therapist attentiveness and empathy. Most families reported improvements in communication and interaction, while the small and non-random sample means the results describe perceptions in this group rather than a guaranteed effect of any specific therapy approach. [3]

A narrative review pulled together animal research on social behavior and described a pattern where basic interest in social contact can be relatively preserved, while more complex skills like social memory and flexible social responding are often weaker in MeCP2-related models. It also discussed brain pathways linked to these behaviors, including reduced BDNF-TrkB signaling, as a way to connect observable behaviors with underlying biology. [4]

For patients and caregivers, these studies mainly add structure to experiences families already recognize: repetitive hand movements can be a prominent challenge, communication supports are often described as helpful, and some social difficulties may involve memory and flexibility more than simple sociability. This evidence may matter now for understanding and tracking day-to-day patterns using caregiver questionnaires and for describing what families value in services, but it does not test or compare specific therapies in a way that can show what works best. [2] [3] [4]

This month’s lab and animal studies stayed focused on the same big question: which measurable brain-and-body changes in Rett models can be shifted toward a healthier direction, and what targets look most promising for future testing. The results were encouraging in places, but they remain early and mostly show partial improvements rather than full normalization. [5] [6] [7] [8]

One preclinical platform screened FDA-approved drugs in Rett patient-derived astrocytes (support cells in the brain) and highlighted mitochondrial problems as a change that could be measured and improved in the dish. Isradipine improved several mitochondrial readouts in Rett astrocytes and neurons, and the study also identified LRRC17 as a secreted factor from astrocytes that could worsen neuronal health, with knockdown improving both mitochondrial and neuron-related measures; isradipine also extended survival in a Rett mouse model. [5]

Two related rat studies looked at auditory brain responses and how vagus nerve stimulation (VNS) paired with sound might shift them. Mecp2+/- rats had weaker and more variable brain responses to speech-like sounds, and VNS partially improved timing and consistency for some stimuli; a separate proteomics study found broad changes in proteins tied to synapses and energy metabolism after VNS-tone pairing, without every difference returning to the wild-type pattern. [6] [7]

In male mice with a Mecp2 mutation, metformin treatment improved a combined set of Rett-like behavioral measures such as gait and breathing irregularities, but it did not restore smaller brain size measures in that model. The study also noted that wild-type mice showed more anxiety-like behavior with metformin in one test, and some treated animals were excluded due to humane endpoints or injuries, showing that animal tolerability and effects can vary by context. [8]

Several studies focused on core biology changes that may help explain symptoms or point toward targets, even if they are not treatments yet. Rett patient fibroblasts showed higher baseline inflammatory signaling with a weaker antioxidant response and a blunted reaction to an immune challenge in the lab, with partial rebalancing when an anti-inflammatory pathway was inhibited and an antioxidant pathway was activated. [9]

Other animal and cell studies expanded the map of affected systems beyond neurons alone. Mecp2-null mice developed progressively lower bone mass with stronger signs of bone breakdown by osteoclasts at later stages, and a mouse exposure study found that a PCB mixture produced gene-expression changes in the cortex that overlapped with MeCP2-mutation effects, including shared changes in oxytocin signaling. [10] [11]

At an even earlier stage, CRISPR-made MECP2 loss-of-function mutations in human stem cells were linked to poorer growth and altered early development in the dish, alongside changes in how DNA is packaged and regulated in 3D. This supports the idea that MECP2 can affect development very early, before mature neurons form, but it does not show how these changes translate to symptoms or treatment response in people. [12]

For families, these studies mostly matter as research steps that help choose what to test next, rather than results that can be applied in care right now. They help clarify that Rett-related changes can involve energy use in cells (mitochondria), brain signaling and sound processing, immune-and-antioxidant balance, and even bone remodeling, and that some of these changes can be shifted in animal or cell models. What remains uncertain is which of these early signals will translate into safe, meaningful benefits for people, since most findings here come from lab systems, rodents, or short-term experiments. [5] [6] [7] [8] [9] [10] [11] [12]

This month’s genetics papers mainly added to the catalog of Rett-related variants and described how different gene changes may relate to clinical severity, while also showing the limits of small samples for drawing firm links. [13] [14]

In 25 Iranian patients with Rett syndrome, researchers reported 15 distinct MECP2 variants and described exon 4 as a hotspot in their sample, including one newly reported frameshift variant. They observed that truncating variants (like nonsense or frameshift changes) appeared to align with more severe features, but the sample size limited how confidently this relationship could be tested statistically. [13]

A case report described a 6-year-old boy with congenital variant Rett syndrome due to a previously unreported, de novo FOXG1 variant, and the authors combined this with a review totaling 10 male cases from the literature. As a single-patient report, it cannot predict outcomes for others, but it expands the known FOXG1 variant spectrum and supports the idea that Rett-like syndromes can arise from genes beyond MECP2. [14]

For patients and caregivers, these reports may matter most for understanding why genetic testing can return many different types of results and why two people with Rett syndrome can look different. They add information that may become more useful over time as variant databases grow, but they do not by themselves predict an individual child or adult's course, especially when studies are small or based on single cases. [13] [14]